Monocytosis and Culprit Vessel in STEMI Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT01569646
First received: June 2, 2010
Last updated: March 30, 2012
Last verified: March 2012
  Purpose

Increased white blood cell count at the onset of an acute ST elevation myocardial infarction has been shown to be associated of increased incidence of heart failure and mortality. Now monocytes which are a subset of white blood cells may have a prognostic value for patients presenting with acute ST segment elevation myocardial infarction. A monocyte count of greater than 800/mm3 following acute myocardial infarction has been shown to be associated with increased incidence of left ventricular dysfunction. The investigators study would retrospectively collect data on patients with ST elevation myocardial infarction, looking for an association between high monocyte count and the culprit vessel causing the myocardial infarction. The investigators would also investigate whether monocytosis would be a marker of poor prognosis.


Condition
STEMI

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Significance of Monocytosis and Culprit Vessel in Patients With Acute ST Elevation Myocardial Infarction

Resource links provided by NLM:


Further study details as provided by North Shore Long Island Jewish Health System:

Primary Outcome Measures:
  • Association between monocyte count and culprit vessel [ Time Frame: 1 day ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • clinical outcomes of troponin and monocyte in stemi patients [ Time Frame: 0 - 6 months ] [ Designated as safety issue: No ]

Enrollment: 226
Study Start Date: April 2008
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

STEMI patients,

Criteria

Inclusion Criteria:

  • STEMI

Exclusion Criteria:

  • Patients on antibiotics and steroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01569646

Locations
United States, New York
Staten Island University Hospital
Staten Island, New York, United States, 10305
Sponsors and Collaborators
North Shore Long Island Jewish Health System
Investigators
Principal Investigator: Duccio Baldari, MD, FACC Staten Island University Hospital
  More Information

No publications provided

Responsible Party: North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier: NCT01569646     History of Changes
Other Study ID Numbers: 08-021
Study First Received: June 2, 2010
Last Updated: March 30, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by North Shore Long Island Jewish Health System:
monocytes
culprit vessels

Additional relevant MeSH terms:
Myocardial Infarction
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on August 28, 2014